The main objective of this study is to demonstrate the benefit of the withdrawal of
Tacrolimus (Prograf®) on renal function in patients one year after the end of the weaning
period. The secondary objectives will focus on assessing the risks and consequences of
withdrawal of Tacrolimus (Prograf®).